30 results on '"Van Laere, Koen"'
Search Results
2. Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
- Author
-
Luckett, Emma S., Abakkouy, Yasmina, Reinartz, Mariska, Adamczuk, Katarzyna, Schaeverbeke, Jolien, Verstockt, Sare, De Meyer, Steffi, Van Laere, Koen, Dupont, Patrick, Cleynen, Isabelle, and Vandenberghe, Rik
- Published
- 2022
- Full Text
- View/download PDF
3. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Tijms, Betty M, Fagan, Anne M, Hansson, Oskar, Klunk, William E, van der Flier, Wiesje M, Villemagne, Victor L, Frisoni, Giovanni B, Fleisher, Adam S, Lleó, Alberto, Mintun, Mark A, Wallin, Anders, Engelborghs, Sebastiaan, Na, Duk L, Chételat, Gäel, Molinuevo, José Luis, Landau, Susan M, Mattsson, Niklas, Kornhuber, Johannes, Sabri, Osama, Rowe, Christopher C, Parnetti, Lucilla, Popp, Julius, Fladby, Tormod, Jagust, William J, Aalten, Pauline, Lee, Dong Young, Vandenberghe, Rik, de Oliveira, Catarina Resende, Kapaki, Elisabeth, Froelich, Lutz, Ivanoiu, Adrian, Gabryelewicz, Tomasz, Verbeek, Marcel M, Sanchez-Juan, Páscual, Hildebrandt, Helmut, Camus, Vincent, Zboch, Marzena, Brooks, David J, Drzezga, Alexander, Rinne, Juha O, Newberg, Andrew, de Mendonça, Alexandre, Sarazin, Marie, Rabinovici, Gil D, Madsen, Karine, Kramberger, Milica G, Nordberg, Agneta, Mok, Vincent, Mroczko, Barbara, Wolk, David A, Meyer, Philipp T, Tsolaki, Magda, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Blennow, Kaj, van Buchem, Mark A, Cavedo, Enrica, Chen, Kewei, Chipi, Elena, Cohen, Ann D, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S, Freund-Levi, Yvonne, Gkatzima, Olymbia, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Johannsen, Peter, Klimkowicz-Mrowiec, Aleksandra, Köhler, Sebastian, Koglin, Norman, van Laere, Koen, de Leon, Mony, Lisetti, Viviana, Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M, Morris, John C, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Perera, Gayan, Peters, Oliver, and Ramakers, Inez HGB
- Subjects
Health Services and Systems ,Health Sciences ,Acquired Cognitive Impairment ,Alzheimer's Disease Related Dementias (ADRD) ,Neurosciences ,Aging ,Dementia ,Brain Disorders ,Behavioral and Social Science ,Neurodegenerative ,Alzheimer's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Mental health ,Aged ,Alzheimer Disease ,Amyloid beta-Peptides ,Brain ,Cognition Disorders ,Cognitive Dysfunction ,Cross-Sectional Studies ,Female ,Humans ,Male ,Memory ,Episodic ,Mental Status and Dementia Tests ,Middle Aged ,Positron-Emission Tomography ,Reference Values ,Amyloid Biomarker Study Group ,Other Medical and Health Sciences ,Psychology ,Cognitive Sciences ,Clinical sciences ,Clinical and health psychology - Abstract
ImportanceCerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.ObjectiveTo investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.Design, setting, and participantsThis cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Main outcomes and measuresGlobal cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.ResultsAmong 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P
- Published
- 2018
4. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.
- Author
-
Wang, Jie, Huang, Qi, He, Kun, Li, Junpeng, Guo, Tengfei, Yang, Yang, Lin, Zengping, Li, Songye, Vanderlinden, Greet, Huang, Yiyun, Van Laere, Koen, Guan, Yihui, Guo, Qihao, Ni, Ruiqing, Li, Binying, and Xie, Fang
- Abstract
INTRODUCTION: Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the pathophysiological mechanism of Alzheimer's disease (AD). METHODS: Ten cognitively impaired (CI) individuals and 10 healthy controls (HCs) underwent [18F]SynVesT‐1 and [18F]PSS232 positron emission tomography (PET)/magnetic resonance to assess synaptic density and mGluR5 availability. The associations between mGluR5 availability and synaptic density were examined. A mediation analysis was performed to investigate the possible mediating effects of mGluR5 availability and synaptic loss on the relationship between amyloid deposition and cognition. RESULTS: CI patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs. Regional synaptic density was closely associated with regional mGluR5 availability. mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and cognition. CONCLUSIONS: Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD and are closely linked. Highlights: Cognitively impaired patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs.Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD.Regional synaptic density was closely associated with regional mGluR5 availability.mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and global cognition.With further research, modulating mGluR5 availability might be a potential therapeutic strategy for improving synaptic function in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults
- Author
-
Schaeverbeke, Jolien M., Gabel, Silvy, Meersmans, Karen, Luckett, Emma S., De Meyer, Steffi, Adamczuk, Katarzyna, Nelissen, Natalie, Goovaerts, Valerie, Radwan, Ahmed, Sunaert, Stefan, Dupont, Patrick, Van Laere, Koen, and Vandenberghe, Rik
- Published
- 2021
- Full Text
- View/download PDF
6. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Knol, Dirk L, Tijms, Betty M, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Bibeau, Kristen, Blennow, Kaj, Brooks, David J, van Buchem, Mark A, Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D, Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M, Fladby, Tormod, Fleisher, Adam S, van der Flier, Wiesje M, Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S, Freund-Levi, Yvonne, Frisoni, Giovanni B, Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J, Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E, Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G, Van Laere, Koen, Landau, Susan M, Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, de Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T, Mintun, Mark A, Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M, Morris, John C, Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L, Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D, Ramakers, Inez HGB, Rami, Lorena, de Oliveira, Catarina Resende, Rinne, Juha O, Rodrigue, Karen M, and Rodríguez-Rodríguez, Eloy
- Subjects
Health Services and Systems ,Health Sciences ,Clinical Research ,Alzheimer's Disease ,Vascular Cognitive Impairment/Dementia ,Acquired Cognitive Impairment ,Neurosciences ,Alzheimer's Disease Related Dementias (ADRD) ,Brain Disorders ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Cerebrovascular ,Neurodegenerative ,Prevention ,Dementia ,Aging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Biomarkers ,Brain ,Cerebrospinal Fluid ,Cognitive Dysfunction ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid Biomarker Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceCerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).Data sourcesRelevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.Study selectionStudies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.Data extraction and synthesisIndividual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.Main outcomes and measuresPrevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.ResultsThe prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.Conclusions and relevanceAmong persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
- Published
- 2015
7. Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
- Author
-
Ossenkoppele, Rik, Jansen, Willemijn J, Rabinovici, Gil D, Knol, Dirk L, van der Flier, Wiesje M, van Berckel, Bart NM, Scheltens, Philip, Visser, Pieter Jelle, Verfaillie, Sander CJ, Zwan, Marissa D, Adriaanse, Sofie M, Lammertsma, Adriaan A, Barkhof, Frederik, Jagust, William J, Miller, Bruce L, Rosen, Howard J, Landau, Susan M, Villemagne, Victor L, Rowe, Christopher C, Lee, Dong Y, Na, Duk L, Seo, Sang W, Sarazin, Marie, Roe, Catherine M, Sabri, Osama, Barthel, Henryk, Koglin, Norman, Hodges, John, Leyton, Cristian E, Vandenberghe, Rik, van Laere, Koen, Drzezga, Alexander, Forster, Stefan, Grimmer, Timo, Sánchez-Juan, Pascual, Carril, Jose M, Mok, Vincent, Camus, Vincent, Klunk, William E, Cohen, Ann D, Meyer, Philipp T, Hellwig, Sabine, Newberg, Andrew, Frederiksen, Kristian S, Fleisher, Adam S, Mintun, Mark A, Wolk, David A, Nordberg, Agneta, Rinne, Juha O, Chételat, Gaël, Lleo, Alberto, Blesa, Rafael, Fortea, Juan, Madsen, Karine, Rodrigue, Karen M, and Brooks, David J
- Subjects
Health Services and Systems ,Health Sciences ,Genetics ,Acquired Cognitive Impairment ,Clinical Research ,Neurodegenerative ,Alzheimer's Disease ,Brain Disorders ,Aging ,Biomedical Imaging ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Brain ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid PET Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceAmyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.Data sourcesThe MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Study selectionCase reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data extraction and synthesisData were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Main outcomes and measuresEstimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.ResultsThe likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P
- Published
- 2015
8. Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
- Author
-
Shuping, Joanna L, Matthews, Dawn C, Adamczuk, Katarzyna, Scott, David, Rowe, Christopher C, Kreisl, William C, Johnson, Sterling C, Lukic, Ana S, Johnson, Keith A, Rosa-Neto, Pedro, Andrews, Randolph D, Van Laere, Koen, Cordes, Lindsay, Ward, Larry, Wilde, Claire L, Barakos, Jerome, Purcell, Derk D, Devanand, Davangere P, Stern, Yaakov, Luchsinger, Jose A, Sur, Cyrille, Price, Julie C, Brickman, Adam M, Klunk, William E, Boxer, Adam L, Mathotaarachchi, Sulantha S, Lao, Patrick J, and Evelhoch, Jeffrey L
- Subjects
Science & Technology ,positron emission tomography ,Clinical Neurology ,Neurosciences ,visual read ,ASSOCIATION ,Alzheimer's disease ,florquinitau ,tracer ,[F-18]MK-6240 ,PATHOLOGY ,VARIABILITY ,Psychiatry and Mental health ,POSITRON-EMISSION-TOMOGRAPHY ,AGE ,neurofibrillary tangles ,Neurosciences & Neurology ,tau ,Neurology (clinical) ,Life Sciences & Biomedicine ,MK-6240 ,ALZHEIMER-DISEASE - Abstract
BACKGROUND: The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within-brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK-6240 use to identify and stage AD subjects versus non-AD and controls. METHODS: Five expert readers used their own methods to assess 30 scans of mixed diagnosis (47% cognitively normal, 23% mild cognitive impairment, 20% AD, 10% traumatic brain injury) and provided input regarding regional and global positivity, features influencing assessment, confidence, practicality, and clinical relevance. Inter-reader agreement and concordance with quantitative values were evaluated to confirm that regions could be read reliably. Guided by input regarding clinical applicability and practicality, read classifications were defined. The readers read the scans using the new classifications, establishing by majority agreement a gold standard read for those scans. Two naïve readers were trained and read the 30-scan set, providing initial validation. Inter-rater agreement was further tested by two trained independent readers in 131 scans. One of these readers used the same method to read a full, diverse database of 1842 scans; relationships between read classification, clinical diagnosis, and amyloid status as available were assessed. RESULTS: Four visual read classifications were determined: no uptake, medial temporal lobe (MTL) only, MTL and neocortical uptake, and uptake outside MTL. Inter-rater kappas were 1.0 for the naïve readers gold standard scans read and 0.98 for the independent readers 131-scan read. All scans in the full database could be classified; classification frequencies were concordant with NFT histopathology literature. DISCUSSION: This four-class [18F]MK-6240 visual read method captures the presence of medial temporal signal, neocortical expansion associated with disease progression, and atypical distributions that may reflect different phenotypes. The method demonstrates excellent trainability, reproducibility, and clinical relevance supporting clinical use. HIGHLIGHTS: A visual read method has been developed for [18F]MK-6240 tau positron emission tomography.The method is readily trainable and reproducible, with inter-rater kappas of 0.98.The read method has been applied to a diverse set of 1842 [18F]MK-6240 scans.All scans from a spectrum of disease states and acquisitions could be classified.Read classifications are consistent with histopathological neurofibrillary tangle staging literature. ispartof: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS vol:9 issue:1 ispartof: location:United States status: published
- Published
- 2023
9. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
- Author
-
Ahmad, Rawaha, Postnov, Andrey, Bormans, Guy, Versijpt, Jan, Vandenbulcke, Mathieu, and Van Laere, Koen
- Published
- 2016
- Full Text
- View/download PDF
10. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
- Author
-
Schaeverbeke, Jolien, Gabel, Silvy, Meersmans, Karen, Bruffaerts, Rose, Liuzzi, Antonietta Gabriella, Evenepoel, Charlotte, Dries, Eva, Van Bouwel, Karen, Sieben, Anne, Pijnenburg, Yolande, Peeters, Ronald, Bormans, Guy, Van Laere, Koen, Koole, Michel, Dupont, Patrick, and Vandenberghe, Rik
- Published
- 2018
- Full Text
- View/download PDF
11. Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B
- Author
-
Adamczuk, Katarzyna, Schaeverbeke, Jolien, Nelissen, Natalie, Neyens, Veerle, Vandenbulcke, Mathieu, Goffin, Karolien, Lilja, Johan, Hilven, Kelly, Dupont, Patrick, Van Laere, Koen, and Vandenberghe, Rik
- Published
- 2016
- Full Text
- View/download PDF
12. Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
- Author
-
Luckett, Emma S., Schaeverbeke, Jolien, De Meyer, Steffi, Adamczuk, Katarzyna, Van Laere, Koen, Dupont, Patrick, and Vandenberghe, Rik
- Subjects
Reference region ,History ,APOE4 ,Polymers and Plastics ,(18)F-Flutemetamol ,Cognitive Neuroscience ,Alzheimer's disease ,18F-Flutemetamol ,Industrial and Manufacturing Engineering ,Amyloid-PET ,Neurology ,Radiology, Nuclear Medicine and imaging ,Neurology (clinical) ,Business and International Management ,Longitudinal study ,Alzheimer’s disease ,Amyloid accumulation - Abstract
Purpose: Measuring longitudinal changes in amyloid load in the asymptomatic stage of Alzheimer’s disease is of high relevance for clinical research and progress towards more efficacious, timely treatments. Apolipoprotein E ε4 (APOE4) has a well-established effect on the rate of amyloid accumulation. Here we investigated which region of interest and which reference region perform best at detecting the effect of APOE4 on longitudinal amyloid load in individuals participating in the Flemish Prevent Alzheimer’s Disease Cohort KU Leuven (F-PACK). Methods: Ninety cognitively intact F-PACK participants (baseline age: 68 (52–80) years, 46 males, 42 APOE4 carriers) received structural MRI and 18F-Flutemetamol PET scans at baseline and follow-up (6.2 (3.4–10.9) year interval). Standardised uptake value ratios (SUVRs) and Centiloids (CLs) were calculated in a composite cortical volume of interest (SUVRcomp/CL) and in the precuneus (SUVRprec), and amyloid rate of change derived: (follow-up amyloid load – baseline amyloid load) / time interval (years). Four reference regions were used to derive amyloid load: whole cerebellum, cerebellar grey matter, eroded subcortical white matter, and pons. Results: When using whole cerebellum or cerebellar grey matter as reference region, APOE4 carriers had a significantly higher SUVRcomp amyloid rate of change than non-carriers (pcorr=0.004, t=3.40 (CI 0.005–0.018); pcorr=0.036, t=2.66 (CI 0.003–0.018), respectively). Significance was not observed for eroded subcortical white matter or pons (pcorr=0.144, t=2.13 (CI 0.0003–0.008); pcorr=0.116, t=2.22 (CI 0.005–0.010), respectively). When using CLs as the amyloid measurement, and whole cerebellum, APOE4 carriers had a higher amyloid rate of change than non-carriers (pcorr=0.012, t=3.05 (CI 0.499–2.359)). Significance was not observed for the other reference regions. No significance was observed with any of the reference regions and amyloid rate of change in the precuneus (SUVRprec). Conclusion: In this cognitively intact cohort, a composite neocortical volume of interest together with whole cerebellum or cerebellar grey matter as reference region are the methods of choice for detecting APOE4-dependent differences in amyloid rate of change.
- Published
- 2023
13. Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET.
- Author
-
Shuping, Joanna L., Matthews, Dawn C., Adamczuk, Katarzyna, Scott, David, Rowe, Christopher C., Kreisl, William C., Johnson, Sterling C., Lukic, Ana S., Johnson, Keith A., Rosa‐Neto, Pedro, Andrews, Randolph D., Van Laere, Koen, Cordes, Lindsay, Ward, Larry, Wilde, Claire L., Barakos, Jerome, Purcell, Derk D., Devanand, Davangere P., Stern, Yaakov, and Luchsinger, Jose A.
- Subjects
POSITRON emission tomography ,NEUROFIBRILLARY tangles ,TAU proteins ,ALZHEIMER'S disease ,BRAIN injuries - Abstract
Background: The positron emission tomography (PET) radiotracer [18F]MK‐6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within‐brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK‐6240 use to identify and stage AD subjects versus non‐AD and controls. Methods: Five expert readers used their own methods to assess 30 scans of mixed diagnosis (47% cognitively normal, 23% mild cognitive impairment, 20% AD, 10% traumatic brain injury) and provided input regarding regional and global positivity, features influencing assessment, confidence, practicality, and clinical relevance. Inter‐reader agreement and concordance with quantitative values were evaluated to confirm that regions could be read reliably. Guided by input regarding clinical applicability and practicality, read classifications were defined. The readers read the scans using the new classifications, establishing by majority agreement a gold standard read for those scans. Two naïve readers were trained and read the 30‐scan set, providing initial validation. Inter‐rater agreement was further tested by two trained independent readers in 131 scans. One of these readers used the same method to read a full, diverse database of 1842 scans; relationships between read classification, clinical diagnosis, and amyloid status as available were assessed. Results: Four visual read classifications were determined: no uptake, medial temporal lobe (MTL) only, MTL and neocortical uptake, and uptake outside MTL. Inter‐rater kappas were 1.0 for the naïve readers gold standard scans read and 0.98 for the independent readers 131‐scan read. All scans in the full database could be classified; classification frequencies were concordant with NFT histopathology literature. Discussion: This four‐class [18F]MK‐6240 visual read method captures the presence of medial temporal signal, neocortical expansion associated with disease progression, and atypical distributions that may reflect different phenotypes. The method demonstrates excellent trainability, reproducibility, and clinical relevance supporting clinical use. Highlights: A visual read method has been developed for [18F]MK‐6240 tau positron emission tomography.The method is readily trainable and reproducible, with inter‐rater kappas of 0.98.The read method has been applied to a diverse set of 1842 [18F]MK‐6240 scans.All scans from a spectrum of disease states and acquisitions could be classified.Read classifications are consistent with histopathological neurofibrillary tangle staging literature. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.
- Author
-
Reinartz, Mariska, Luckett, Emma Susanne, Schaeverbeke, Jolien, De Meyer, Steffi, Adamczuk, Katarzyna, Thal, Dietmar Rudolf, Van Laere, Koen, Dupont, Patrick, and Vandenberghe, Rik
- Subjects
OLDER people ,AMYLOID plaque ,ALZHEIMER'S disease ,RECEIVER operating characteristic curves ,SUPPORT vector machines ,GRAIN yields - Abstract
Purpose: End-of-life studies have validated the binary visual reads of
18 F-labeled amyloid PET tracers as an accurate tool for the presence or absence of increased neuritic amyloid plaque density. In this study, the performance of a support vector machine (SVM)-based classifier will be tested against pathological ground truths and its performance determined in cognitively healthy older adults. Methods: We applied SVM with a linear kernel to an18 F-Flutemetamol end-of-life dataset to determine the regions with the highest feature weights in a data-driven manner and to compare between two different pathological ground truths: based on neuritic amyloid plaque density or on amyloid phases, respectively. We also trained and tested classifiers based on the 10% voxels with the highest amplitudes of feature weights for each of the two neuropathological ground truths. Next, we tested the classifiers' diagnostic performance in the asymptomatic Alzheimer's disease (AD) phase, a phase of interest for future drug development, in an independent dataset of cognitively intact older adults, the Flemish Prevent AD Cohort-KU Leuven (F-PACK). A regression analysis was conducted between the Centiloid (CL) value in a composite volume of interest (VOI), as index for amyloid load, and the distance to the hyperplane for each of the two classifiers, based on the two pathological ground truths. A receiver operating characteristic analysis was also performed to determine the CL threshold that optimally discriminates between neuritic amyloid plaque positivity versus negativity, or amyloid phase positivity versus negativity, within F-PACK. Results: The classifiers yielded adequate specificity and sensitivity within the end-of-life dataset (neuritic amyloid plaque density classifier: specificity of 90.2% and sensitivity of 83.7%; amyloid phase classifier: specificity of 98.4% and sensitivity of 84.0%). The regions with the highest feature weights corresponded to precuneus, caudate, anteromedial prefrontal, and also posterior inferior temporal and inferior parietal cortex. In the cognitively normal cohort, the correlation coefficient between CL and distance to the hyperplane was −0.66 for the classifier trained with neuritic amyloid plaque density, and −0.88 for the classifier trained with amyloid phases. This difference was significant. The optimal CL cut-off for discriminating positive versus negative scans was CL = 48–51 for the different classifiers (area under the curve (AUC) = 99.9%), except for the classifier trained with amyloid phases and based on the 10% voxels with highest feature weights. There the cut-off was CL = 26 (AUC = 99.5%), which closely matched the CL threshold for discriminating phases 0–2 from 3–5 based on the end-of-life dataset and the neuropathological ground truth. Discussion: Among a set of neuropathologically validated classifiers trained with end-of-life cases, transfer to a cognitively normal population works best for a classifier trained with amyloid phases and using only voxels with the highest amplitudes of feature weights. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
- Author
-
Nordberg, Agneta, Carter, Stephen F., Rinne, Juha, Drzezga, Alexander, Brooks, David J., Vandenberghe, Rik, Perani, Daniela, Forsberg, Anton, Långström, Bengt, Scheinin, Noora, Karrasch, Mira, Någren, Kjell, Grimmer, Timo, Miederer, Isabelle, Edison, Paul, Okello, Aren, Van Laere, Koen, Nelissen, Natalie, Vandenbulcke, Mathieu, Garibotto, Valentina, Almkvist, Ove, Kalbe, Elke, Hinz, Rainer, and Herholz, Karl
- Published
- 2013
- Full Text
- View/download PDF
16. Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.
- Author
-
De Meyer, Steffi, Vanbrabant, Jeroen, Schaeverbeke, Jolien M., Reinartz, Mariska, Luckett, Emma S., Dupont, Patrick, Van Laere, Koen, Stoops, Erik, Vanmechelen, Eugeen, Poesen, Koen, and Vandenberghe, Rik
- Subjects
ALZHEIMER'S disease ,RECEIVER operating characteristic curves ,CEREBRAL cortex ,TAU proteins - Abstract
Objective: Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross‐reacts with p‐tau175. This study investigates two novel phospho‐specific assays for plasma p‐tau181 and p‐tau231 in clinical and asymptomatic AD. Methods: Plasma p‐tau species were quantified with Simoa in 44 AD patients, 40 spouse controls and an independent cohort of 151 cognitively unimpaired (CU) elderly who underwent Aβ‐PET. Simoa plasma Aβ42 measurements were available in a CU subset (N = 69). Receiver operating characteristics and Aβ‐PET associations were used to evaluate biomarker validity. Results: The novel plasma p‐tau181 and p‐tau231 assays did not show cross‐reactivity. Plasma p‐tau181 accurately detected clinical AD (area under the curve (AUC) = 0.98, 95% CI 0.95–1.00) as well as asymptomatic Aβ pathology (AUC = 0.84, 95% CI 0.76–0.92), while plasma p‐tau231 did not (AUC = 0.74, 95% CI 0.63–0.85 and 0.61, 95% CI 0.52–0.71, respectively). Plasma p‐tau181, but not p‐tau231, detected asymptomatic Aβ pathology more accurately than age, sex and APOE combined (AUC = 0.64). In asymptomatic elderly, correlations between plasma p‐tau181 and Aβ pathology were observed throughout the cerebral cortex (ρ = 0.40, p < 0.0001), with focal associations within AD‐vulnerable regions, particularly the precuneus. The plasma Aβ42/p‐tau181 ratio did not reflect asymptomatic Aβ pathology better than p‐tau181 alone. Interpretation: The novel plasma p‐tau181 assay is an accurate tool to detect clinical as well as asymptomatic AD and provides a phospho‐specific alternative to currently employed immunoassays. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau-PET load in cognitively intact older adults.
- Author
-
Schaeverbeke, Jolien, Luckett, Emma S., Gabel, Silvy, Reinartz, Mariska, De Meyer, Steffi, Cleynen, Isabelle, Sleegers, Kristel, Van Broeckhoven, Christine, Bormans, Guy, Serdons, Kim, Van Laere, Koen, Dupont, Patrick, and Vandenberghe, Rik
- Subjects
OLDER people ,ALZHEIMER'S disease ,MILD cognitive impairment ,APOLIPOPROTEIN E ,INTEGRATORS - Abstract
Introduction: The bridging integrator 1(BIN1) rs744373 risk polymorphism has been linked to increased [18F]AV1451 signal in non-demented older adults (ie., mild cognitive impairment [MCI] plus cognitively normal [CN] individuals). However, the association of BIN1 with in vivo tau, amyloid beta (Aß) burden, and cognitive impairment in the asymptomatic stage of Alzheimer's disease (AD) remains unknown. Methods: The BIN1 effect on [18F]AV1451 binding was evaluated in 59 cognitively normal (CN) participants (39% apolipoprotein E [APOE e4]) from the Flemish Prevent AD Cohort KU Leuven (F-PACK), as well as in 66 Alzheimer's Disease Neuroimaging Initiative (ADNI) CNparticipants, using voxelwise and regional statistics. For comparison, 52 MCI patients from ADNI were also studied. Results: Forty-four percent of F-PACK participants were BIN1 rs744373 risk-allele carriers, 21% showed high amyloid burden, and 8% had elevated [18F]AV1451 binding. In ADNI, 53% and 50% of CNs and MCIs, respectively, carried the BIN1 rs744373 risk-allele. Amyloid positivity was present in 23% of CNs and 51% of MCIs, whereas 2% of CNs and 35% of MCIs showed elevated [18F]AV1451 binding. There was no significant effect of BIN1 on voxelwise or regional [18F]AV1451 in F-PACK or ADNI CNs, or in the pooled CN sample. No significant association between BIN1 and [18F]AV1451 was obtained in ADNI MCI patients. However, in the MCI group, numerically higher [18F]AV1451 binding was observed in the BIN1 risk-allele group compared to the BIN1 normal group in regions corresponding to more progressed tau pathology. Discussion: We could not confirm the association between BIN1 rs744373 riskallele and elevated [18F]AV1451 signal in CN older adults or MCI. Numerically higher [18F]AV1451 binding was observed, however, in theMCI BIN1 risk-allele group, indicating that the previously reported positive effect may be confounded by group. Therefore, when studying how the BIN1 risk polymorphism influences AD pathogenesis, a distinction should bemade between asymptomatic, MCI, and dementia stages of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Changes in the language system as amyloid-β accumulates.
- Author
-
Reinartz, Mariska, Gabel, Silvy, Schaeverbeke, Jolien, Meersmans, Karen, Adamczuk, Katarzyna, Luckett, Emma Susanne, Meyer, Steffi De, Laere, Koen Van, Sunaert, Stefan, Dupont, Patrick, Vandenberghe, Rik, De Meyer, Steffi, and Van Laere, Koen
- Subjects
LINGUISTIC change ,TEMPORAL lobe ,FUNCTIONAL magnetic resonance imaging ,NEURAL circuitry ,ALZHEIMER'S disease ,RESEARCH ,CROSS-sectional method ,RESEARCH methodology ,LANGUAGE & languages ,MAGNETIC resonance imaging ,EVALUATION research ,COMPARATIVE studies ,AGING ,RESEARCH funding ,PEPTIDES ,LONGITUDINAL method ,EMISSION-computed tomography - Abstract
Language dysfunction is common in Alzheimer's disease. There is increasing interest in the preclinical or asymptomatic phase of Alzheimer's disease. Here we examined in 35 cognitively intact older adults (age range 52-78 years at baseline, 17 male) in a longitudinal study design the association between accumulation of amyloid over a 5-6-year period, measured using PET, and functional changes in the language network measured over the same time period using task-related functional MRI. In the same participants, we also determined the association between the longitudinal functional MRI changes and a cross-sectional measure of tau load as measured with 18F-AV1451 PET. As predicted, the principal change occurred in posterior temporal cortex. In the cortex surrounding the right superior temporal sulcus, the response amplitude during the associative-semantic versus visuo-perceptual task increased over time as amyloid load accumulated (Pcorrected = 0.008). In a whole-brain voxel-wise analysis, amyloid accumulation was also associated with a decrease in response amplitude in the left inferior frontal sulcus (Pcorrected = 0.009) and the right dorsomedial prefrontal cortex (Pcorrected = 0.005). In cognitively intact older adults, cross-sectional tau load was not associated with longitudinal changes in functional MRI response amplitude. Our findings confirm the central role of the neocortex surrounding the posterior superior temporal sulcus as the area of predilection within the language network in the earliest stages of Alzheimer's disease. Amyloid accumulation has an impact on cognitive brain circuitry in the asymptomatic phase of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression.
- Author
-
Takamiya, Akihiro, Vande Casteele, Thomas, Koole, Michel, De Winter, François-Laurent, Bouckaert, Filip, Van den Stock, Jan, Sunaert, Stefan, Dupont, Patrick, Vandenberghe, Rik, Van Laere, Koen, Vandenbulcke, Mathieu, and Emsell, Louise
- Subjects
GRAY matter (Nerve tissue) ,MENTAL depression ,ALZHEIMER'S disease ,PATHOLOGICAL physiology ,BRAIN tomography - Abstract
Late-life depression (LLD) is associated with a risk of developing Alzheimer's disease (AD). However, the role of AD-pathophysiology in LLD, and its association with clinical symptoms and cognitive function are elusive. In this study, one hundred subjects underwent amyloid positron emission tomography (PET) imaging with [
18 F]-flutemetamol and structural MRI: 48 severely depressed elderly subjects (age 74.1 ± 7.5 years, 33 female) and 52 age-/gender-matched healthy controls (72.4 ± 6.4 years, 37 female). The Geriatric Depression Scale (GDS) and Rey Auditory Verbal Learning Test (RAVLT) were used to assess the severity of depressive symptoms and episodic memory function respectively. Amyloid deposition was quantified using the standardized uptake value ratio. Whole-brain voxel-wise comparisons of amyloid deposition and gray matter volume (GMV) between LLD and controls were performed. Multivariate analysis of covariance was conducted to investigate the association of regional differences in amyloid deposition and GMV with clinical factors, including GDS and RAVLT. As a result, there were no significant group differences in amyloid deposition. In contrast, LLD showed significant lower GMV in the left temporal and parietal region. GMV reduction in the left temporal region was associated with episodic memory dysfunction, but not with depression severity. Regional GMV reduction was not associated with amyloid deposition. LLD is associated with lower GMV in regions that overlap with AD-pathophysiology, and which are associated with episodic memory function. The lack of corresponding associations with amyloid suggests that lower GMV driven by non-amyloid pathology may play a central role in the neurobiology of LLD presenting as a psychiatric disorder. Trial registration: European Union Drug Regulating Authorities Clinical Trials identifier: EudraCT 2009-018064-95. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients.
- Author
-
Schaeverbeke, Jolien, Celen, Sofie, Cornelis, Julie, Ronisz, Alicja, Serdons, Kim, Van Laere, Koen, Thal, Dietmar Rudolf, Tousseyn, Thomas, Bormans, Guy, and Vandenberghe, Rik
- Subjects
APHASIC persons ,FRONTOTEMPORAL lobar degeneration ,ALZHEIMER'S disease ,FRONTOTEMPORAL dementia ,TEMPORAL lobe - Abstract
Purpose: In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic variant primary progressive aphasia (SV PPA) has consistently been reported. This is unexpected as the majority of these patients have frontotemporal lobar degeneration TDP (FTLD-TDP). Methods: We conducted an in vitro [
18 F]AV1451 autoradiography binding study in five cases with a clinical diagnosis of SV PPA constituting the range of pathologies (i.e., three FTLD-TDP, one Alzheimer's disease (AD), and one Pick's disease (PiD)). Binding was compared with two controls without neurodegeneration, two typical AD, one corticobasal syndrome with underlying AD, and one frontotemporal dementia behavioral variant with FTLD-TDP. The effect of blocking with the authentic reference material and with the MAO-B inhibitor deprenyl was assessed. Immunohistochemistry was performed on adjacent cryosections. Results: Absence of specific [18 F]AV1451 binding was observed for all three SV PPA FTLD-TDP cases. The absence of binding in controls as well as the successful blocking with authentic AV1451 in cases with tauopathy demonstrated specificity of the [18 F]AV1451 signal for tau. The specific [18 F]AV1451 binding was highest in AD, followed by PiD. This binding colocalized with the respective tau lesions and could not be blocked by deprenyl. Similar pilot findings were obtained with [18 F]THK5351. Conclusion: In vitro autoradiography showed no [18 F]AV1451 binding in SV PPA due to FTLD-TDP, while specific binding was present in SV PPA due to AD and PiD. The discrepancy between in vitro and in vivo findings remains to be explained. The discordance is not related to [18 F]AV1451 idiosyncrasies as [18 F]THK5351 findings were similar. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.
- Author
-
Koole, Michel, Lohith, Talakad G., Valentine, John L., Bennacef, Idriss, Declercq, Ruben, Reynders, Tom, Riffel, Kerry, Celen, Sofie, Serdons, Kim, Bormans, Guy, Ferry-Martin, Sandrine, Laroque, Philippe, Walji, Abbas, Hostetler, Eric D., Briscoe, Richard J., de Hoon, Jan, Sur, Cyrille, Van Laere, Koen, and Struyk, Arie
- Subjects
POSITRON emission tomography ,NEUROFIBRILLARY tangles ,RADIATION dosimetry ,INTRAVENOUS injections ,DIAGNOSTIC imaging ,BRAIN imaging ,RESEARCH ,NEURONS ,ALZHEIMER'S disease ,HUMAN research subjects ,RADIATION measurements ,ANIMAL experimentation ,RESEARCH methodology ,ISOQUINOLINE ,RADIOISOTOPES ,EVALUATION research ,MEDICAL cooperation ,FLUORINE isotopes ,RATS ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,PATIENT safety - Abstract
Purpose: [18F]MK-6240 is a selective, high-affinity positron emission tomography tracer for imaging neurofibrillary tangles, a key pathological signature that correlates with cognitive decline in Alzheimer disease. This report provides safety information from preclinical toxicology studies and first-in-human whole-body biodistribution and dosimetry studies of [18F]MK-6240 for its potential application in human brain imaging studies.Procedures: MK-6240 was administered intravenously (IV) in a 7-day rat toxicity study at × 50, × 100, and × 1000 dose margins relative to projected highest clinical dose of 0.333 μg/kg. The IV formulation of MK-6240 for clinical use and the formulation used in the 7-day rat toxicity study was tested for hemolysis potential in human and Wistar rat whole blood. Sequential whole-body positron emission tomography scans were performed in three healthy young subjects after IV bolus injection of 180 ± 0.3 MBq [18F]MK-6240 to characterize organ biodistribution and estimate whole-body radiation exposure (effective dose).Results: MK-6240 administered IV in a 7-day rat toxicity study did not show any test article-related changes. The no-observed-adverse-effect level in rats was ≥ 333 μg/kg/day which provides a margin 1000-fold over an anticipated maximum clinical dose of 0.333 μg/kg. Additionally, the MK-6240 formulation was not hemolytic in human or Wistar rat blood. [18F]MK-6240 activity was widely distributed to the brain and the rest of the body, with organ absorbed doses largest for the gall bladder (202 μGy/MBq). The average (±SD) effective dose was 29.4 ± 0.6 μSv/MBq, which is in the typical range for F-18 radiolabeled ligands.Conclusions: Microdoses of [18F]MK-6240 are safe for clinical positron emission tomography imaging studies. Single IV administration of 185 MBq (5 mCi) [18F]MK-6240 is anticipated to result in a total human effective dose of 5.4 mSv and thus allows multiple positron emission tomography scans of the same subject per year. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. No Association of Lower Hippocampal Volume With Alzheimer's Disease Pathology in Late-Life Depression.
- Author
-
De Winter, François-Laurent, Emsell, Louise, Bouckaert, Filip, Claes, Lene, Jain, Saurabh, Farrar, Gill, Billiet, Thibo, Evers, Stephan, Van Den Stock, Jan, Sienaert, Pascal, Obbels, Jasmien, Sunaert, Stefan, Adamczuk, Katarzyna, Vandenberghe, Rik, Van Laere, Koen, and Vandenbulcke, Mathieu
- Subjects
DIAGNOSIS of depression in old age ,HIPPOCAMPUS diseases ,NEUROBEHAVIORAL disorders ,ALZHEIMER'S disease diagnosis ,MAGNETIC resonance imaging ,DEPRESSION in old age ,PREVENTION ,DIAGNOSIS ,PROTEIN metabolism ,ALZHEIMER'S disease ,AMINES ,ANTHROPOMETRY ,CEREBRAL cortex ,MENTAL depression ,DIAGNOSTIC imaging ,FLUORINE isotopes ,HIPPOCAMPUS (Brain) ,COMPUTERS in medicine ,RADIOISOTOPES ,REFERENCE values ,STATISTICS ,THIAZOLES ,POSITRON emission tomography ,THREE-dimensional imaging ,ATROPHY ,EARLY diagnosis - Abstract
Objective: Hippocampal volume is commonly decreased in late-life depression. According to the depression-as-late-life-neuropsychiatric-disorder model, lower hippocampal volume in late-life depression is associated with neurodegenerative changes. The purpose of this prospective study was to examine whether lower hippocampal volume in late-life depression is associated with Alzheimer's disease pathology.Method: Of 108 subjects who participated, complete, good-quality data sets were available for 100: 48 currently depressed older adults and 52 age- and gender-matched healthy comparison subjects who underwent structural MRI, [18F]flutemetamol amyloid positron emission tomography imaging, apolipoprotein E genotyping, and neuropsychological assessment. Hippocampal volumes were defined manually and normalized for total intracranial volume. Amyloid binding was quantified using the standardized uptake value ratio in one cortical composite volume of interest. The authors investigated group differences in hippocampal volume (both including and excluding amyloid-positive participants), group differences in amyloid uptake and in the proportion of positive amyloid scans, and the association between hippocampal volume and cortical amyloid uptake.Results: A significant difference was observed in mean normalized total hippocampal volume between patients and comparison subjects, but there were no group differences in cortical amyloid uptake or proportion of amyloid-positive subjects. The difference in hippocampal volume remained significant after the amyloid-positive subjects were excluded. There was no association between hippocampal volume and amyloid uptake in either patients or comparison subjects.Conclusions: Lower hippocampal volume was not related to amyloid pathology in this sample of patients with late-life depression. These data counter the common belief that changes in hippocampal volume in late-life depression are due to prodromal Alzheimer's disease. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.
- Author
-
Declercq, Lieven D., Vandenberghe, Rik, Van Laere, Koen, Verbruggen, Alfons, and Bormans, Guy
- Subjects
ALZHEIMER'S disease treatment ,POSITRON emission tomography ,SINGLE-photon emission computed tomography - Abstract
Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major concerns. Non-invasive molecular imaging techniques, positron emission tomography and single photon emission (computed) tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of (patho)physiological processes and allow early (differential) diagnosis in many disorders. PET and SPECT have the ability to provide biomarkers that permit spatial assessment of pathophysiological molecular changes and therefore objectively evaluate and follow up therapeutic response, especially in the brain. A number of specific PET/SPECT biomarkers used in support of emerging clinical therapies in AD are discussed in this review. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Amyloid imaging in cognitively normal older adults: comparison between F-flutemetamol and C-Pittsburgh compound B.
- Author
-
Adamczuk, Katarzyna, Schaeverbeke, Jolien, Nelissen, Natalie, Neyens, Veerle, Vandenbulcke, Mathieu, Goffin, Karolien, Lilja, Johan, Hilven, Kelly, Dupont, Patrick, Van Laere, Koen, and Vandenberghe, Rik
- Subjects
ALZHEIMER'S disease ,BIOMARKERS ,DRUG development ,RANK correlation (Statistics) ,RADIOPHARMACEUTICALS - Abstract
Purpose: Preclinical, or asymptomatic, Alzheimer's disease (AD) refers to the presence of positive AD biomarkers in the absence of cognitive deficits. This research concept is being applied to define target populations for clinical drug development. In a prospective community-recruited cohort of cognitively intact older adults, we compared two amyloid imaging markers within subjects: F-flutemetamol and C-Pittsburgh compound B (PIB). Methods: In 32 community-recruited cognitively intact older adults aged between 65 and 80 years, we determined the concordance between binary classification based on F-flutemetamol versus C-PIB according to semiquantitative assessment (standardized uptake value ratio in composite cortical volume, SUVR) and, alternatively, according to visual reads. We also determined the correlation between F-flutemetamol and C-PIB SUVR and evaluated how this was affected by the reference region chosen (cerebellar grey matter versus pons) and the use of partial volume correction (PVC) in this population. Results: Binary classification based on semiquantitative assessment was concordant between F-flutemetamol and C-PIB in 94 % of cases. Concordance of blinded binary visual reads between tracers was 84 %. The Spearman correlation between F-flutemetamol and C-PIB SUVR with cerebellar grey matter as reference region was 0.84, with a slope of 0.98. Correlations in neocortical regions were significantly lower with the pons as reference region. PVC improved the correlation in striatum and medial temporal cortex. Conclusion: For the definition of preclinical AD based on F-flutemetamol, concordance with C-PIB was highest using semiquantitative assessment with cerebellar grey matter as reference region. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. 3D Shape Perception in Posterior Cortical Atrophy: A Visual Neuroscience Perspective.
- Author
-
Gillebert, Céline R., Schaeverbeke, Jolien, Bastin, Christine, Neyens, Veerle, Bruffaerts, Rose, De Weer, An-Sofie, Seghers, Alexandra, Sunaert, Stefan, Van Laere, Koen, Versijpt, Jan, Vandenbulcke, Mathieu, Salmon, Eric, Todd, James T., Orban, Guy A., and Vandenberghe, Rik
- Subjects
CEREBRAL atrophy ,FORM perception ,VISUAL perception ,NEURODEGENERATION ,GRAY matter (Nerve tissue) - Abstract
Posterior cortical atrophy (PCA) is a rare focal neurodegenerative syndrome characterized by progressive visuoperceptual and visuospatial deficits, most often due to atypical Alzheimer's disease (AD). We applied insights from basic visual neuroscience to analyze 3D shape perception in humans affected by PCA. Thirteen PCA patients and 30 matched healthy controls participated, together with two patient control groups with diffuse Lewy body dementia (DLBD) and an amnestic-dominant phenotype of AD, respectively. The hierarchical study design consisted of 3D shape processing for 4 cues (shading, motion, texture, and binocular disparity) with corresponding 2D and elementary feature extraction control conditions. PCA and DLBD exhibited severe 3D shape-processing deficits and AD to a lesser degree. In PCA, deficient 3D shape-from-shading was associated with volume loss in the right posterior inferior temporal cortex. This region coincided with a region of functional activation during 3D shape-from-shading in healthy controls. In PCA patients who performed the same fMRI paradigm, response amplitude during 3D shape-from-shading was reduced in this region. Gray matter volume in this region also correlated with 3D shape-from-shading in AD. 3D shape-from-disparity in PCA was associated with volume loss slightly more anteriorly in posterior inferior temporal cortex as well as in ventral premotor cortex. The findings in right posterior inferior temporal cortex and right premotor cortex are consistent with neurophysiologically based models of the functional anatomy of 3D shape processing. However, in DLBD, 3D shape deficits rely on mechanisms distinct from inferior temporal structural integrity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Assessment of Neuroinflammation and Microglial Activation in Alzheimer’s Disease with Radiolabelled PK11195 and Single Photon Emission Computed Tomography.
- Author
-
Versijpt, Jan J., Dumont, Filip, Van Laere, Koen J., Decoo, Danny, Santens, Patrick, Audenaert, Kurt, Achten, Eric, Slegers, Guido, Dierckx, Rudi A., and Korf, Jakob
- Subjects
ALZHEIMER'S disease ,INFLAMMATION ,MICROGLIA ,BENZODIAZEPINE receptors ,TOMOGRAPHY - Abstract
Objectives: Inflammation contributes to degeneration in Alzheimer’s disease (AD), not simply as a secondary phenomenon, but primarily as a significant source of pathology. [[sup 123] I]iodo-PK11195 is a single photon emission computed tomography (SPECT) ligand for the peripheral benzodiazepine receptor, the latter being expressed on microglia (brain resident macrophages) and upregulated under inflammatory circumstances. The objectives were to assess AD inflammation by detecting [[sup 123] I]iodo-PK11195 uptake changes and investigate how uptake values relate with perfusion SPECT and neuropsychological findings. Methods: Ten AD and 9 control subjects were included. [[sup 123] I]iodo-PK11195 SPECT images were realigned into stereotactic space where binding indices, normalized on cerebellar uptake, were calculated. Results: The mean [[sup 123] I]iodo-PK11195 uptake was increased in AD patients compared with controls in nearly all neocortical regions; however, statistical significance was only reached in the frontal and right mesotemporal regions. Significant correlations were found between regional increased [[sup 123] I]iodo-PK11195 uptake and cognitive deficits. Conclusions: [[sup 123] I]iodo-PK11195 is a cellular disease activity marker and allows in vivo assessment of microglial inflammation in AD.Copyright © 2003 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
27. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease.
- Author
-
Ahmad, Rawaha, Goffin, Karolien, Van den Stock, Jan, De Winter, François-Laurent, Cleeren, Evy, Bormans, Guy, Tournoy, Jos, Persoons, Philippe, Van Laere, Koen, and Vandenbulcke, Mathieu
- Subjects
- *
CANNABINOID receptors , *NEUROPROTECTIVE agents , *HOMEOSTASIS , *ALZHEIMER'S patients , *COGNITIVE ability , *APOLIPOPROTEIN E , *MAGNETIC resonance imaging of the brain - Abstract
The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain. In Alzheimer's disease (AD), the role of type 1 cannabinoid receptor (CB1R) is unclear, with contradictory findings in post-mortem studies showing upregulation, downregulation or unchanged CB1R status. We have investigated CB1R availability in vivo in patients with AD, in relation to amyloid deposition, cognitive functioning and apolipoprotein E (ApoE) genotype. Eleven AD patients and 7 healthy volunteers (HV) underwent combined [18F]MK-9470 PET and [11C]PIB PET scans to assess CB1R availability and amyloid deposition, respectively, and T1 volumetric MRI for partial volume correction. We found no difference in CB1R availability between AD and HV, VOI-based fractional uptake values (FUR) were 0.043±0.01 for AD and 0.045±0.01 for controls (p=0.9). CB1R availability did not correlate with neuropsychological test scores and was not modulated by ApoE genotype. As expected, global [11C]PIB SUVR (standardized uptake value ratio) was increased in AD (SUVR 1.9±0.3) compared to HV (1.2±0.1) with p<0.001, but no correlation was found between amyloid β (Aβ) deposition and CB1R availability. In conclusion, we found no in vivo evidence for a difference in CB1R availability in AD compared to age-matched controls. Taken together with recently reported in vivo CB1R changes in Parkinson's and Huntington's disease, these data suggest that the CB1R is differentially involved in neurodegenerative disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease.
- Author
-
Emsell, Louise, Vanhaute, Heleen, Vansteelandt, Kristof, De Winter, François-Laurent, Christiaens, Danny, Van den Stock, Jan, Vandenberghe, Rik, Van Laere, Koen, Sunaert, Stefan, Bouckaert, Filip, and Vandenbulcke, Mathieu
- Subjects
- *
ALZHEIMER'S disease , *MEDICAL protocols , *DIFFERENTIAL diagnosis , *MAGNETIC resonance imaging , *MENTAL depression , *POSITRON emission tomography - Abstract
• HV discriminated depression from AD in half of cases in a psychiatry setting. • MRI can be used to identify patients who would benefit from amyloid assessment. • Combining amyloid PET with HV improves the differential diagnosis of AD and LLD. Amyloid positron emission tomography (PET) and hippocampal volume derived from magnetic resonance imaging may be useful clinical biomarkers for differentiating between geriatric depression and Alzheimer's disease (AD). Here we investigated the incremental value of using hippocampal volume and 18F-flutemetmol amyloid PET measures in tandem and sequentially to improve discrimination in unclassified participants. Two approaches were compared in 41 participants with geriatric depression and 27 participants with probable AD: (1) amyloid and hippocampal volume combined in one model and (2) classification based on hippocampal volume first and then subsequent stratification using standardized uptake value ratio (SUVR)-determined amyloid positivity. Hippocampal volume and amyloid SUVR were significant diagnostic predictors of depression (sensitivity: 95%, specificity: 89%). 51% of participants were correctly classified according to clinical diagnosis based on hippocampal volume alone, increasing to 87% when adding amyloid data (sensitivity: 94%, specificity: 78%). Our results suggest that hippocampal volume may be a useful gatekeeper for identifying depressed individuals at risk for AD who would benefit from additional amyloid biomarkers when available. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI
- Author
-
Vandenberghe, Rik, Nelissen, Natalie, Salmon, Eric, Ivanoiu, Adrian, Hasselbalch, Steen, Andersen, Allan, Korner, Alex, Minthon, Lennart, Brooks, David J., Van Laere, Koen, and Dupont, Patrick
- Subjects
- *
POSITRON emission tomography , *MAGNETIC resonance imaging , *AMYLOID , *ALZHEIMER'S disease , *SUPPORT vector machines , *MACHINE learning , *DIAGNOSTIC imaging - Abstract
Abstract: 18F-flutemetamol is a positron emission tomography (PET) tracer for in vivo amyloid imaging. The ability to classify amyloid scans in a binary manner as ‘normal’ versus ‘Alzheimer-like’, is of high clinical relevance. We evaluated whether a supervised machine learning technique, support vector machines (SVM), can replicate the assignments made by visual readers blind to the clinical diagnosis, which image components have highest diagnostic value according to SVM and how 18F-flutemetamol-based classification using SVM relates to structural MRI-based classification using SVM within the same subjects. By means of SVM with a linear kernel, we analyzed 18F-flutemetamol scans and volumetric MRI scans from 72 cases from the 18F-flutemetamol phase 2 study (27 clinically probable Alzheimer''s disease (AD), 20 amnestic mild cognitive impairment (MCI), 25 controls). In a leave-one-out approach, we trained the 18F-flutemetamol based classifier by means of the visual reads and tested whether the classifier was able to reproduce the assignment based on visual reads and which voxels had the highest feature weights. The 18F-flutemetamol based classifier was able to replicate the assignments obtained by visual reads with 100% accuracy. The voxels with highest feature weights were in the striatum, precuneus, cingulate and middle frontal gyrus. Second, to determine concordance between the gray matter volume- and the 18F-flutemetamol-based classification, we trained the classifier with the clinical diagnosis as gold standard. Overall sensitivity of the 18F-flutemetamol- and the gray matter volume-based classifiers were identical (85.2%), albeit with discordant classification in three cases. Specificity of the 18F-flutemetamol based classifier was 92% compared to 68% for MRI. In the MCI group, the 18F-flutemetamol based classifier distinguished more reliably between converters and non-converters than the gray matter-based classifier. The visual read-based binary classification of 18F-flutemetamol scans can be replicated using SVM. In this sample the specificity of 18F-flutemetamol based SVM for distinguishing AD from controls is higher than that of gray matter volume-based SVM. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease
- Author
-
Karl Herholz, Noora M. Scheinin, Agneta Nordberg, Kjell Någren, A Okello, Koen Van Laere, Juha O. Rinne, Rik Vandenberghe, Ove Almkvist, Bengt Långström, Timo Grimmer, Anton Forsberg, Isabelle Miederer, Valentina Garibotto, Natalie Nelissen, Daniela Perani, David J. Brooks, Elke Kalbe, Mathieu Vandenbulcke, Stephen F. Carter, Alexander Drzezga, Paul Edison, Mira Karrasch, Rainer Hinz, Nordberg, Agneta, Nullf, nullCarter Stephen, Rinne, Juha, Drzezga, Alexander, Nullj, nullBrooks David, Vandenberghe, Rik, Perani, DANIELA FELICITA L., Forsberg, Anton, Langstrom, Bengt, Scheinin, Noora, Karrasch, Mira, Nagren, Kjell, Grimmer, Timo, Miederer, Isabelle, Edison, Paul, Okello, Aren, Van Laere, Koen, Nelissen, Natalie, Vandenbulcke, Mathieu, Garibotto, Valentina, Almkvist, Ove, Kalbe, Elke, Hinz, Rainer, and Herholz, Karl
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Amyloid ,Amyloid/analysis ,Neurology ,Alzheimer Disease/diagnostic imaging ,Amyloid pet ,Disease ,ddc:616.0757 ,Cognition ,Apolipoproteins E ,Alzheimer Disease ,mental disorders ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Apolipoproteins E/analysis ,Brain Chemistry ,Aniline Compounds ,PIB ,business.industry ,Mild cognitive impairment ,Brain ,General Medicine ,Multicentre PET ,Middle Aged ,Brain/diagnostic imaging ,medicine.disease ,MCI ,Europe ,Thiazoles ,Amyloid deposition ,Multicenter study ,Radiology Nuclear Medicine and imaging ,Case-Control Studies ,Positron-Emission Tomography ,Biomarker (medicine) ,Original Article ,Female ,Alzheimer's disease ,Radiopharmaceuticals ,business ,Alzheimer’s disease - Abstract
Purpose Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimer’s disease (AD). To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies. Methods In this study 238 [11C]Pittsburgh compound-B (PIB) datasets from five different European centres were pooled. Of these 238 datasets, 18 were excluded, leaving [11C]PIB datasets from 97 patients with clinically diagnosed AD (mean age 69 ± 8 years), 72 patients with mild cognitive impairment (MCI; mean age 67.5 ± 8 years) and 51 healthy controls (mean age 67.4 ± 6 years) available for analysis. Of the MCI patients, 64 were longitudinally followed for 28 ± 15 months. Most participants (175 out of 220) were also tested for apolipoprotein E (ApoE) genotype. Results [11C]PIB retention in the neocortical and subcortical brain regions was significantly higher in AD patients than in age-matched controls. Intermediate [11C]PIB retention was observed in MCI patients, with a bimodal distribution (64 % MCI PIB-positive and 36 % MCI PIB-negative), which was significantly different the pattern in both the AD patients and controls. Higher [11C]PIB retention was observed in MCI ApoE ε4 carriers compared to non-ApoE ε4 carriers (p
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.